Inspiremd Inc (NSPR) Stock Price, Quote & News

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as w...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 776 6804

Website: www.inspiremd.com

Address:

6303 Waterford District Drive, Suite 215, Miami, United States

zigsfrd Feb. 23 at 2:48 PM

$NSPR Is the Medtronic device still in development or is it an approved product.

1 · Reply

LoyalShark Feb. 23 at 1:11 PM

$NSPR in talking with a couple cardiologists that have just begun using the Cguard - they are impressed. First validation from an actual user of the the CGuard I have gotten . AGAIN - one of the things that they said was that they have the moral and legal obligation to bring the best best outcome to thier patients using the products they are qualified to use. SO - as the learning curve reaches more and more health systems the liability leans to having to use the CGuard to protect themselves from 'attys'

2 · Reply

GiveHerTheDD Feb. 19 at 2:54 PM

$NSPR 2nd manufacturing line opening up in North Carolina. Demand must be surging?

4 · Reply

LoyalShark Feb. 17 at 7:51 PM

$NSPR So what do you all want to know about NSPR. I will find out best I can. If we need to have our own conference calls we will. If the we need to replace a BOD person ... we will try to do that . This is our company - lets take it over. Slosman wants to be a dick. We be a bigger dick. If Webb Campbell cant get his head out of his ass...we let him struggle and do his job the right way. We need more retainl investors in the stock to create value. Retail , in the equity markets, creates the safe haven for institutions. Tutes need liquidity...or a PIPE or other offering ot get in when there is not retail. That is our problem. As in the world of commodities it is the retail investor / speculator that creates liquididty for the markets. Everytime. Pretty simple. Ignore building a following and strong retail commnication and touches....and you end up with your currency sucking like InspireMd's has for 5 yrs. Creates excess dilution. We can do this. Its an incredible product.

2 · Reply

LoyalShark Feb. 17 at 6:34 PM

$NSPR PR It is probably time to put the shoe on the other foot and fix the disaster Slosman has created. I put in a complaint with Schwab about not being able to buy the stock. I filed a compalint with the SEC on Fidelity for limiting the number of shares that could be sold. I put in a call to the BD's I used to walk the halls of to see if we can get some kind of research coverage....first question ...'can you set up a meeting with the CFO or CEO'....which unfortunately since they do not return phone calls or texts or messages or emails...the answer was no...which makes ZERO sense to them or me or you. I called BOA and asked why they are not following NSPR given they did the last PIPE and made a hell of a lot of money off us. Doing the heavy lifting because Webb Campbell - the IR guy has no idea how to properly help a microcap company create value. Maybe the worst IR guy I have ever met. So we will see where it goes. Going Bullish because I am stepping it up.

1 · Reply

HOBOWITHASHOTGUN Feb. 17 at 5:40 PM

$NSPR So this was interesting reading... https://www.medtronic.com/en-us/c/healthcare-professionals/peripheral-vascular-health/neuroguard-iep-system.html?cid=PPC:BING:HCP-NB-Procedure-RSA:AMEROLM-CV-PVH-Neuroguard-19722474&ef_id=b379585d21051b8020bd31c987039ba2:G:s&s_kwcid=AL!18272!10!82807380835650!!!!82808651945026!!688875568!1324914195675963&msclkid=b379585d21051b8020bd31c987039ba2

2 · Reply

MarketLeverage Feb. 17 at 3:33 PM

$NSPR InspireMD develops stroke prevention devices, with clinical adoption dependent on procedural evidence and reimbursement.

0 · Reply

HOBOWITHASHOTGUN Feb. 13 at 8:12 PM

$NSPR Nice volume...

0 · Reply

OfficialStocktwitsUser Feb. 13 at 2:11 AM

$NSPR RSI: 60.53, MACD: -0.0150 Vol: 0.06, MA20: 1.66, MA50: 1.79 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

HOBOWITHASHOTGUN Feb. 12 at 4:53 PM

$NSPR holding our own - though on ridiculously thin volume - on a bloodbath day...

0 · Reply

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2026, 9:00 AM EST - 6 weeks ago

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

Nov 24, 2025, 7:30 AM EST - 3 months ago

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

Nov 19, 2025, 4:42 PM EST - 3 months ago

InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

Nov 4, 2025, 1:06 PM EST - 3 months ago

InspireMD, Inc. (NSPR) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:00 AM EST - 3 months ago

InspireMD Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 7:30 AM EST - 4 months ago

InspireMD Names Peter A. Soukas, M.D.

Oct 21, 2025, 4:05 PM EDT - 4 months ago

InspireMD to Announce Third Quarter 2025 Financial Results

Sep 17, 2025, 8:00 AM EDT - 5 months ago

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

Aug 27, 2025, 9:00 AM EDT - 6 months ago

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 12:30 PM EDT - 7 months ago

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 7 months ago

InspireMD Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 8:31 AM EDT - 7 months ago

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

Jul 31, 2025, 8:30 AM EDT - 7 months ago

InspireMD Announces Combined Financings of $58 Million

Jul 22, 2025, 7:00 AM EDT - 7 months ago

InspireMD to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 7:00 AM EDT - 8 months ago

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 24, 2025, 4:05 PM EDT - 8 months ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 13, 2025, 9:00 AM EDT - 9 months ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

Jun 3, 2025, 4:05 PM EDT - 9 months ago

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

May 9, 2025, 12:07 PM EDT - 10 months ago

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:00 AM EDT - 10 months ago

InspireMD Reports First Quarter 2025 Financial Results

Apr 30, 2025, 9:00 AM EDT - 10 months ago

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Apr 25, 2025, 9:00 AM EDT - 10 months ago

InspireMD to Announce First Quarter 2025 Financial Results

Mar 26, 2025, 9:00 AM EDT - 11 months ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 12, 2025, 1:53 PM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 7:00 AM EDT - 1 year ago

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 1 year ago

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 7:00 AM EST - 1 year ago

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Dec 9, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Nov 25, 2024, 4:05 PM EST - 1 year ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 12, 2024, 10:20 AM EST - 1 year ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Oct 15, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Aug 9, 2024, 8:58 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 8:09 AM EDT - 1 year ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:00 AM EDT - 1 year ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Jul 30, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

May 28, 2024, 8:53 AM EDT - 1 year ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 14, 2024, 10:50 AM EDT - 1 year ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

Apr 3, 2024, 8:59 AM EDT - 2 years ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 2 years ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 6, 2024, 11:30 AM EST - 2 years ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:00 AM EST - 2 years ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 2 years ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

Feb 12, 2024, 7:00 AM EST - 2 years ago

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Jan 31, 2024, 7:00 AM EST - 2 years ago

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

Jan 3, 2024, 7:00 AM EST - 2 years ago

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

zigsfrd Feb. 23 at 2:48 PM

$NSPR Is the Medtronic device still in development or is it an approved product.

1 · Reply

LoyalShark Feb. 23 at 1:11 PM

2 · Reply

GiveHerTheDD Feb. 19 at 2:54 PM

$NSPR 2nd manufacturing line opening up in North Carolina. Demand must be surging?

4 · Reply

LoyalShark Feb. 17 at 7:51 PM

2 · Reply

LoyalShark Feb. 17 at 6:34 PM

1 · Reply

HOBOWITHASHOTGUN Feb. 17 at 5:40 PM

2 · Reply

MarketLeverage Feb. 17 at 3:33 PM

$NSPR InspireMD develops stroke prevention devices, with clinical adoption dependent on procedural evidence and reimbursement.

0 · Reply

HOBOWITHASHOTGUN Feb. 13 at 8:12 PM

$NSPR Nice volume...

0 · Reply

OfficialStocktwitsUser Feb. 13 at 2:11 AM

0 · Reply

HOBOWITHASHOTGUN Feb. 12 at 4:53 PM

$NSPR holding our own - though on ridiculously thin volume - on a bloodbath day...

0 · Reply

zigsfrd Feb. 12 at 4:03 PM

$NSPR Just patiently waiting to wakeup some morning and find this at 15 bucks.

2 · Reply

LoyalShark Feb. 12 at 3:30 AM

$NSPR The management is hiding from shareholders.

0 · Reply

Jonnie5 Feb. 11 at 1:17 PM

$NSPR can’t help but wonder if this stock will run next month on sector rotation, record sales revenue and any hint at future buyout or partnership.

1 · Reply

TradeGloom Feb. 10 at 2:11 PM

$NSPR is a biotech (InspireMD) focused on vascular protection; requires clinical adoption and reimbursement.

0 · Reply

LoyalShark Feb. 9 at 7:34 PM

$NSPR At this point - in my opinion - the only way shareholders win is a buyout sooner than later. Has ANYONE tried calling the company? I have many many times and dont get a return call or email -- nothing. ANYONE TRIED CALLING THE COMPANY????

1 · Reply

RedDogSailor Feb. 9 at 4:54 PM

$NSPR up so much on no volume 🤷‍♂️

0 · Reply

LoyalShark Feb. 8 at 1:27 PM

$NSPR Thin about it. IF you can only buy a few shares at a time. Think of what that means to the supply demand of the stock. You have a guy selling 2,000 shares....lunch money, It takes 10 trades to eat that 2000 shares. Its not an efficient market. It has not been an efficient market since Slosman took over. It doesn't have to be this way.

0 · Reply

HOBOWITHASHOTGUN Feb. 6 at 2:49 PM

$NSPR Correction - 400 shares apparently...

0 · Reply

HOBOWITHASHOTGUN Feb. 6 at 2:46 PM

$NSPR Just bought 1,000 more $NSPR & about 1,000 more $PZG on Schwab, but had to buy them in small increments. Wouldn't take a full one-time 1,000 share order on either. 100 to 200 shares at a time. Pain in the ass obviously, but can be done.

1 · Reply

arcuy Feb. 6 at 12:19 AM

$NSPR getting tired of it. I'll buy more

0 · Reply

zigsfrd Feb. 4 at 4:17 PM

$NSPR I don't think Gleason selling shares means a damn thing, other than pocket change for him. With this company more than 80% owned by tutes and insiders, with limited liquidity. The name your price and volume aspect of trading reminds me of a privately held company that will sell, but only for a certain prespecified price.

2 · Reply

Shadowsdontlie Feb. 4 at 3:47 PM

$NSPR Sell the company. That is the answer. Sell the Company while there is still cash in the bank and gleam its eye. Sell the company. Typically a long quiet period like NSPR is indicates those talks could be real. With NSPR the problem is they have never been good at communication so its hard to tell what is happening from silence. Its more the norm than not. Sell the company.

0 · Reply

Market Cap	76.69M
Revenue (ttm)	7.01M
Net Income (ttm)	-32.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-456.63%
Debt to Equity Ratio	0.00

Volume	9,338
Avg Vol	39,146
Day's Range	N/A - N/A
Shares Out	42.37M
Stochastic %K	78%
Beta	0.93
Analysts	Strong Sell
Price Target	$5.00